Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2004 Apr;48(4):1413-5.

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.

Author information

1
International Clinical Virology, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire SG1 2NY, United Kingdom.

Abstract

Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (with reduced susceptibility to all three inhibitors) and then Y115F. TFV-containing regimens might increase K65R selection, which confers multiple nucleoside reverse transcriptase inhibitor resistance.

PMID:
15047556
PMCID:
PMC375323
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center